-
Something wrong with this record ?
Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs
V. Pekarik, J. Gumulec, M. Masarik, R. Kizek, V. Adam,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Drug Resistance, Neoplasm MeSH
- Cytostatic Agents pharmacology MeSH
- Humans MeSH
- Metallothionein genetics metabolism MeSH
- MicroRNAs genetics metabolism MeSH
- Prostatic Neoplasms diagnosis drug therapy genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
MicroRNAs (miRNAs) translationally repressing their target messenger RNAs due to their gene-regulatory functions play an important but not unexpected role in a tumour development. More surprising are the findings that levels of various miRNAs are well correlated with presence of specific tumours and formation of metastases. Moreover, these small regulatory molecules play a role in the resistance of cancer cells to commonly used anti-cancer drugs, such as cisplatin, anthracyclines, and taxanes. In that respect, miRNAs become very attractive target for potential therapeutic interventions. Improvements in the sensitivity of miRNAs detection techniques led to discovery of circulating miRNAs which became very attractive non-invasive biomarker of cancer with a substantial predictive value. In this review, the authors focus on i) oncogenic and anti-tumour acting miRNAs, ii) function of miRNAs in tumour progression, iii) possible role of miRNAs in resistance to anticancer drugs, and iv) diagnostic potential of miRNAs for identification of cancer from circulating miRNAs with special emphasis on prostate cancer. Moreover, relationship between miRNAs and expression of metallothionein is discussed as a possible explanation of resistance against platinum based drugs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14051223
- 003
- CZ-PrNML
- 005
- 20171209135436.0
- 007
- ta
- 008
- 140401s2013 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/0929867311320040005 $2 doi
- 035 __
- $a (PubMed)23157640
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Pekarik, V
- 245 10
- $a Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs / $c V. Pekarik, J. Gumulec, M. Masarik, R. Kizek, V. Adam,
- 520 9_
- $a MicroRNAs (miRNAs) translationally repressing their target messenger RNAs due to their gene-regulatory functions play an important but not unexpected role in a tumour development. More surprising are the findings that levels of various miRNAs are well correlated with presence of specific tumours and formation of metastases. Moreover, these small regulatory molecules play a role in the resistance of cancer cells to commonly used anti-cancer drugs, such as cisplatin, anthracyclines, and taxanes. In that respect, miRNAs become very attractive target for potential therapeutic interventions. Improvements in the sensitivity of miRNAs detection techniques led to discovery of circulating miRNAs which became very attractive non-invasive biomarker of cancer with a substantial predictive value. In this review, the authors focus on i) oncogenic and anti-tumour acting miRNAs, ii) function of miRNAs in tumour progression, iii) possible role of miRNAs in resistance to anticancer drugs, and iv) diagnostic potential of miRNAs for identification of cancer from circulating miRNAs with special emphasis on prostate cancer. Moreover, relationship between miRNAs and expression of metallothionein is discussed as a possible explanation of resistance against platinum based drugs.
- 650 _2
- $a cytostatické látky $x farmakologie $7 D054697
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metalothionein $x genetika $x metabolismus $7 D008668
- 650 _2
- $a mikro RNA $x genetika $x metabolismus $7 D035683
- 650 _2
- $a nádory prostaty $x diagnóza $x farmakoterapie $x genetika $x metabolismus $7 D011471
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Gumulec, J $u -
- 700 1_
- $a Masarik, M $u -
- 700 1_
- $a Kizek, R $u -
- 700 1_
- $a Adam, Vojtěch $u - $7 xx0064599 $4
- 773 0_
- $w MED00001274 $t Current medicinal chemistry $x 1875-533X $g Roč. 20, č. 4 (2013), s. 534-44
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23157640 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140401 $b ABA008
- 991 __
- $a 20140411102934 $b ABA008
- 999 __
- $a ok $b bmc $g 1018359 $s 849803
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 20 $c 4 $d 534-44 $i 1875-533X $m Current medicinal chemistry $n Curr Med Chem $x MED00001274
- LZP __
- $a Pubmed-20140401